Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Aug 29, 2018
The first “potentiators” of mutant CFTRs, which rescue their defective chloride channel function, were identified by high-throughput screening and reported by Dr. Verkman’s lab in 2003, and in 2005 they reported the first “correctors” of defective cellular processing of the deltaF508 CFTR mutant. Dr. Verkman provides a comprehensive overview of the history and future of CFTR modulators, advances in “CFTR-agnostic” therapies, and other hopes for transformative CF therapeutic options.